These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23070275)

  • 1. Endothelin antagonists in hypertension and kidney disease.
    Meyers KE; Sethna C
    Pediatr Nephrol; 2013 May; 28(5):711-20. PubMed ID: 23070275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
    Mirabito Colafella KM; Neves KB; Montezano AC; Garrelds IM; van Veghel R; de Vries R; Uijl E; Baelde HJ; van den Meiracker AH; Touyz RM; Danser AHJ; Versmissen J
    Cardiovasc Res; 2020 Aug; 116(10):1779-1790. PubMed ID: 31593221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
    Rothermund L; Kossmehl P; Neumayer HH; Paul M; Kreutz R
    J Hypertens; 2003 Dec; 21(12):2389-97. PubMed ID: 14654760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin ETA receptor antagonism in cardiovascular disease.
    Nasser SA; El-Mas MM
    Eur J Pharmacol; 2014 Aug; 737():210-3. PubMed ID: 24952955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
    Bądzyńska B; Vaneckova I; Sadowski J; Hojná S; Kompanowska-Jezierska E
    Eur J Pharmacol; 2021 Nov; 910():174445. PubMed ID: 34492284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
    Vernerová Z; Kujal P; Kramer HJ; Bäcker A; Cervenka L; Vaneckova I
    Physiol Res; 2009; 58 Suppl 2():S69-S78. PubMed ID: 20131938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster.
    Honoré JC; Fecteau MH; Brochu I; Labonté J; Bkaily G; D'Orleans-Juste P
    Am J Physiol Heart Circ Physiol; 2005 Sep; 289(3):H1258-64. PubMed ID: 15879484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
    Goddard J; Johnston NR; Hand MF; Cumming AD; Rabelink TJ; Rankin AJ; Webb DJ
    Circulation; 2004 Mar; 109(9):1186-93. PubMed ID: 14981006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
    Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin and endothelin receptors in the renal and cardiovascular systems.
    Vignon-Zellweger N; Heiden S; Miyauchi T; Emoto N
    Life Sci; 2012 Oct; 91(13-14):490-500. PubMed ID: 22480517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.
    Iglarz M; Steiner P; Wanner D; Rey M; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):332-7. PubMed ID: 25992919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endothelin system in pulmonary arterial hypertension.
    Galié N; Manes A; Branzi A
    Cardiovasc Res; 2004 Feb; 61(2):227-37. PubMed ID: 14736539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
    Harris AK; Elgebaly MM; Li W; Sachidanandam K; Ergul A
    Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1213-9. PubMed ID: 18287215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis.
    Seccia TM; Caroccia B; Gioco F; Piazza M; Buccella V; Guidolin D; Guerzoni E; Montini B; Petrelli L; Pagnin E; Ravarotto V; Belloni AS; Calò LA; Rossi GP
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27444511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung.
    Janosi T; Peták F; Fontao F; Morel DR; Beghetti M; Habre W
    Exp Physiol; 2008 Nov; 93(11):1210-9. PubMed ID: 18567602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
    El-Mas MM; Helmy MW; Ali RM; El-Gowelli HM
    Toxicol Appl Pharmacol; 2015 Apr; 284(1):1-7. PubMed ID: 25656942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
    Sachidanandam K; Elgebaly MM; Harris AK; Hutchinson JR; Mezzetti EM; Portik-Dobos V; Ergul A
    Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2743-9. PubMed ID: 18424628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: Is there still hope for the future?
    Vaněčková I; Hojná S; Kadlecová M; Vernerová Z; Kopkan L; Červenka L; Zicha J
    Physiol Res; 2018 Jun; 67(Suppl 1):S55-S67. PubMed ID: 29947528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vivo interaction of nitric oxide and endothelin.
    Hocher B; Schwarz A; Slowinski T; Bachmann S; Pfeilschifter J; Neumayer HH; Bauer C
    J Hypertens; 2004 Jan; 22(1):111-9. PubMed ID: 15106802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms.
    Suga S; Yasui N; Yoshihara F; Horio T; Kawano Y; Kangawa K; Johnson RJ
    J Am Soc Nephrol; 2003 Feb; 14(2):397-406. PubMed ID: 12538740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.